Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab

By sjmartinez • August 30, 2024

Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. J Clin Oncol. 2024 Aug 28:JCO2400645. doi: 10.1200/JCO.24.00645. Epub ahead of print. PMID: 39197119.

Tags: Hematology/Oncology, Publications

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors

Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira[...]

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis

Britten K, Lipsyc-Sharf M, Yang EH, McCloskey S, Sedrak MS, Teshome M, LaBarbera J, Bardia A, McAndrew N. Socioeconomic disparities in long-term heart failure risk[...]